Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$0.00$0.00— vs Q1 2020 Net Income-$127.84K-$127.84KN/M vs Q1 2020 EPS Diluted$0.00$0.00— vs Q1 2020 Operating Income-$167,753N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 14, 2021 · 44 d after period end